New research at LANL and the Wellcome Trust Sanger Institute shows a molecular fingerprint in stomach cancer that shows it can be treated with platinum drugs and/or molecular inhibitors known as PARP. Courtesy/LANL
Therapy has potential to save lives of thousands of cancer patients each year
New research from a multidisciplinary team shows that a molecular fingerprint, termed “signature 3,” is found in stomach cancer, opening the door to potential treatment with therapies such as platinum drugs.
This finding has the potential to save thousand of lives a year by delivering a more
State Nation World National Laboratory Healthcare